Department of Oncology, Affiliated Hospital of Binzhou Medical University, China.
Department of Chest Surgery, Affiliated Hospital of Binzhou Medical University, China.
Int J Genomics. 2014;2014:846142. doi: 10.1155/2014/846142. Epub 2014 Aug 5.
Background. Osteopontin (OPN) is associated with prognosis of patients with non-small-cell lung cancer (NSCLC). However, little is known about the association between OPN gene polymorphism and the chemotherapy response in NSCLC patients. Methods. A total of 497 patients with inoperable advanced stage of NSCLC (stages III B and IV NSCLC) were enrolled. All patients had received platinum-based chemotherapy. OPN gene polymorphisms at 156 GG/G, 443 C/T, and -66T/G were determined. Results. The genotypes and allele frequency of -443C>T were significantly different between the responders and nonresponders. Responders had a markedly higher frequency of -443TT genotype than responders (40.71% versus 19.09%, P < 0.001). With CC as reference, the TT genotype carriers had a higher chance to be well responders (adjusted OR = 4.43, 95% CI: 2.60-7.53, adjusted P < 0.001). The median overall survival time for patients with -443CC, -443CT, and -443TT genotype carriers was significantly different. Multivariate Cox proportional hazards regression models showed that OPN -443C>T gene polymorphisms were closely correlated to poor NSCLC prognosis. Conclusion. OPN -443C>T gene polymorphism may be used as a molecular marker to predict the treatment response to chemotherapy in advanced NSCLC patients.
骨桥蛋白（OPN）与非小细胞肺癌（NSCLC）患者的预后相关。然而，OPN 基因多态性与 NSCLC 患者化疗反应之间的关系知之甚少。
共纳入 497 例无法手术的晚期 NSCLC（III B 和 IV 期 NSCLC）患者。所有患者均接受了铂类为基础的化疗。检测 OPN 基因 156 GG/G、443 C/T 和-66T/G 多态性。
-443C>T 的基因型和等位基因频率在应答者和无应答者之间存在显著差异。应答者中-443TT 基因型的频率明显高于无应答者（40.71%比 19.09%，P<0.001）。以 CC 为参照，TT 基因型携带者成为完全应答者的可能性更高（调整 OR=4.43，95%CI：2.60-7.53，调整 P<0.001）。-443CC、-443CT 和-443TT 基因型携带者的总生存时间中位数存在显著差异。多因素 Cox 比例风险回归模型显示，OPN-443C>T 基因多态性与 NSCLC 不良预后密切相关。
OPN-443C>T 基因多态性可作为预测晚期 NSCLC 患者化疗反应的分子标志物。
